David C. Hastings
2021 - Arbutus Biopharma Corp
In 2021, David C. Hastings earned a total compensation of $1.5M as Chief Financial Officer at Arbutus Biopharma Corp.
Compensation breakdown
| Non-Equity Incentive Plan | $201,066 |
|---|---|
| Option Awards | $809,435 |
| Salary | $437,100 |
| Other | $8,934 |
| Total | $1,456,535 |
Hastings received $809.4K in option awards, accounting for 56% of the total pay in 2021.
Hastings also received $201.1K in non-equity incentive plan, $437.1K in salary and $8.9K in other compensation.
Rankings
In 2021, David C. Hastings' compensation ranked 7,374th out of 12,406 executives tracked by ExecPay. In other words, Hastings earned more than 40.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,374 out of 12,406 | 41st |
Division Manufacturing | 3,238 out of 5,492 | 41st |
Major group Chemicals And Allied Products | 1,433 out of 2,368 | 40th |
Industry group Drugs | 1,276 out of 2,089 | 39th |
Industry Pharmaceutical Preparations | 936 out of 1,536 | 39th |
Source: SEC filing on April 11, 2022.
Hastings' colleagues
We found two more compensation records of executives who worked with David C. Hastings at Arbutus Biopharma Corp in 2021.